AbbVie and Myriad Genetics expand Tumor BRACAnalysis CDx collaboration
 

Myriad Genetics, Inc. announced today that it has signed an expanded companion diagnostic agreement with AbbVie, Inc., a leading global biopharmaceutical company to use Tumor BRACAnalysis CDx™ as a companion diagnostic in support of AbbVie’s novel poly (ADP-ribose) polymerase or PARP inhibitor, veliparib.

More...